Sanofi's HIV Vaccine Positive, But Historical Efficacy 'Modest'
By Donna Young
Friday, September 25, 2009
WASHINGTON - A U.S.-funded, Thailand-run, 16,000-patient Phase III study of Sanofi-Aventis Group SA's ALVAC HIV and VaxGen Inc.'s AIDSVAX B/E found that the prime-boost investigational vaccine regimen cut HIV infections by 31.2 percent - the first time an HIV vaccine candidate successfully reduced the risk of HIV infection in humans. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.